
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Stock analysts at HC Wainwright raised their FY2026 EPS estimates for Nektar Therapeutics in a research report issued on Monday, November 16th. HC Wainwright analyst A. He now forecasts that the biopharmaceutical company will post earnings per share of ($7.06) for the year, up from their previous estimate of ($7.49). HC Wainwright currently has a “Buy” rating and a $185.00 price target on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($7.53) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q4 2026 earnings at ($2.38) EPS, Q1 2027 earnings at ($2.45) EPS, Q2 2027 earnings at ($1.01) EPS, Q3 2027 earnings at ($2.62) EPS, Q4 2027 earnings at ($2.29) EPS, FY2027 earnings at ($8.40) EPS, FY2028 earnings at ($9.23) EPS, FY2029 earnings at ($6.08) EPS and FY2030 earnings at $0.59 EPS.
A number of other research analysts also recently commented on the stock. UBS Group initiated coverage on shares of Nektar Therapeutics in a research report on Monday, October 12th. They issued a “neutral” rating and a $53.00 price objective for the company. Wall Street Zen cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Leerink Partners initiated coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They issued an “outperform” rating and a $130.00 target price for the company. TD Cowen upgraded shares of Nektar Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Wedbush reduced their price target on Nektar Therapeutics from $80.00 to $50.00 and set a “neutral” rating for the company in a report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.33.
Check Out Our Latest Report on NKTR
Nektar Therapeutics Price Performance
Shares of NKTR stock opened at $35.91 on Wednesday. The stock has a market cap of $1.23 billion, a P/E ratio of -5.56 and a beta of 1.44. The company has a fifty day moving average price of $46.93 and a two-hundred day moving average price of $64.55. Nektar Therapeutics has a one year low of $33.40 and a one year high of $109.00.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.07) by $0.44. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 29.31%. The business had revenue of $9.39 million for the quarter, compared to the consensus estimate of $10.27 million.
Institutional Trading of Nektar Therapeutics
Hedge funds have recently modified their holdings of the stock. Two Seas Capital LP boosted its holdings in shares of Nektar Therapeutics by 8.2% during the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock worth $202,582,000 after buying an additional 253,744 shares during the period. Goldman Sachs Group Inc. grew its stake in Nektar Therapeutics by 171.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 621,249 shares of the biopharmaceutical company’s stock valued at $37,614,000 after buying an additional 392,759 shares during the last quarter. Braidwell LP grew its stake in Nektar Therapeutics by 112.7% in the 2nd quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock valued at $33,063,000 after buying an additional 250,916 shares during the last quarter. Orbimed Advisors LLC acquired a new position in Nektar Therapeutics in the 1st quarter valued at about $19,786,000. Finally, ADAR1 Capital Management LLC raised its holdings in Nektar Therapeutics by 123.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 161,252 shares of the biopharmaceutical company’s stock valued at $11,602,000 after acquiring an additional 89,221 shares during the period. Institutional investors and hedge funds own 75.88% of the company’s stock.
Nektar Therapeutics News Roundup
Here’s some of the latest news about NKTR:
- Positive Sentiment: HC Wainwright lifted its EPS forecasts across 2026–2029, reflecting smaller projected losses, and raised its 2030 estimate to $0.59 from $0.35, implying a move to profitability in that year. The firm maintained its Buy rating and $185 price target. HC Wainwright rating and outlook
- Neutral Sentiment: Canaccord Genuity lowered its target to $149 from $153 but kept a Buy rating. The reduced target is a modest negative, while the continued Buy stance remains supportive.
- Negative Sentiment: Despite the improved estimates, HC Wainwright still projects substantial losses through 2029. That continuing cash- and earnings-pressure outlook may limit the impact of the longer-term profitability forecast on the stock.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Featured Stories
- Five stocks we like better than Nektar Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
